國家衛生研究院 NHRI:Item 3990099045/2872
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 908723      Online Users : 1044
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2872


    Title: Topoisomerase 2 alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia
    Authors: Liu, JM;Wang, LS;Huang, MH;Hsu, WH;Yen, SH;Shiau, CY;Li, AFY;Tiu, CM;Tseng, SW;Huang, BS
    Contributors: National Institute of Cancer Research
    Abstract: BACKGROUND. Microsatellite studies in histologic types B3 and C thymic neoplasia detected gains on chromosome 17q, which contains the Her-2/neu and its juxtaposed topoisomerase 2 alpha (T2 alpha) genes. The study aimed to evaluate their impact on tumor biology and survival of advanced thymic neoplasia patients. METHODS. From 1991 to 2005, 36 consecutive stage IV thymic carcinoma patients were treated, 18 men and 18 women, aged 11 to 84 years. There were 22 thymic carcinoma, 13 type 133, and 1 type B2 thymoma. Patients received treatment consisting of surgical resection, combination chemotherapy with the CAP (cyclophosphamide, Adriamycin, cisplatin) regimen, or radiation therapy potentiated by high-dose weekly 5-fluorouracil infusion. Permutations of these 3 treatment modalities were prescribed as necessary. RESULTS. T2 alpha gene amplification was detected in 4 of 14 thymic carcinoma and I of 15 type 133 thymoma. Three thymic carcinoma patients had Her-2/neu coamplification and these 3 patients had rapidly growing tumor and extensive disease at initial diagnosis. CAP was prescribed in 28 patients and 20 patients responded (response rate, 71.4%, 95% confidence interval [CI]: 52.8% to 85%); all responders overexpressed (>= 10% nuclei positive) the T2 alpha protein, whereas 4 nonresponders had very low expression. T2a overexpression predicts CAP response, and its absence predicts resistance (P = .001). Overall survival was significantly prolonged if the tumor was resectable (P = .001), of type 133 histology (P = .0039), and had no Her-2 gene amplification (P = .0081). CONCLUSIONS. T2 alpha and Her-2/neu genes play a pivotal role in the tumor biology, CAP response, and survival of advanced thymic neoplasia patients.
    Keywords: Oncology
    Date: 2007-02-01
    Relation: Cancer. 2007 Feb;109(3):502-509.
    Link to: http://dx.doi.org/10.1002/cncr.22404
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0008-543X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000243869700006
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33846682699
    Appears in Collections:[Szu-Wen Tseng(1997-2007)] Periodical Articles
    [Ming Jacqueline Liu(1996-2007)] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    000243869700006.pdf285KbAdobe PDF1571View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback